Background: Sentinel node biopsy (SNB) has been proposed as an alternative to axillary lymph-node dissection (ALND) in breast cancer. Before implementing SNB in our practice, we wished to test its validity by comparing it to the standard ALND, both in our hands and with other reported series.
Introduction
In the new era of early diagnosis of breast cancer, with fewer patients presenting with nodal involvement [1] , routine axillary lymph node dissection (ALND) has been criticised as an adjunct to the standard surgical treatment. The core of such criticism is that there is no apparent survival benefit associated with ALND, which is done only for staging purposes. On the other hand, the prognosis of breast cancer patients may be established on tumour-derived factors rather than on nodal status [2] [3] [4] . Nevertheless, it is generally accepted that the procedure is necessary in order to achieve a complete evaluation of nodal status, which remains pivotal for the subsequent management and decision-making concerning adjuvant therapy, according to the International Consensus Panel on Primary Breast Cancer [5] . In such scenario, the appearance of the Sentinel Node Biopsy (SNB) can contribute to end the debate, as it may bring about the information we need on nodal spreading without much surgical invasiveness [6] . The principle of the SNB practice relies on its ability to accurately predict the 'true' nodal status of any given patient. Hence we felt that the validity of the technique should be tested in the clinical setting before abandoning the well-established practice of complete ALND. At least by our social and cultural standards, this should be done in a very convincing way. Here we report on our assessment of the technique, based on a prospective study that was conducted during a two-year period at a university hospital of the Barcelona area. In order to reinforce our conclusions and achieve a more precise and global evaluation of SNB, we also present with the results of a meta-analysis that was conducted to include all the available data in the literature, that is, a 'pooled data' analysis. The bottom line of such analysis is that with most reported series sensitivities are in the range of 90% or more, however, these results stem from limited numbers of cases. Accordingly, the lower limit for the 95% confidence sensitivity interval may plunge down to 50%, making the decision to abandon ALND very difficult to take on a single-study basis. Therefore, our approach was to combine all the available sensitivities, including our own, by applying a meta-analytic method for diagnostic studies [7] .
Patients and methods
From October 1997 to November 1999, 132 patients were prospectively entered into the study. In every patient, ALND followed SNB immediately and was used as a reference for comparison. Included were patients scheduled for primary surgical treatment of a recently diagnosed breast cancer less than 5 cm in size. Most of them came from our Breast Disease Unit after a diagnosis based on a fine needle aspiration or a 'Core' biopsy. Excluded were patients with clinically enlarged axillary nodes and a positive nodal FNA biopsy, as well as those with locally advanced or disseminated breast cancer, previous axillary surgery or radiotherapy, and primary chemotherapy.
The technique for SNB has been described elsewhere [8] . In short, between 20 and 2 hours before surgery, 3 to 4 doses of technetium-99m labelled microcolloidal albumin, which has a particle size between 200 and more than 1000 nm, were interstitially injected around the tumour: 11 MBq per dose in two ml saline, for a total injection volumen of 6 ml. In nonpalpable lesions, the localizing wire was used to guide the intraparenchymal injection of the tracer. Immediate presurgical lymphoscintigraphic images were taken using at least two views: anterior and anterior oblique at 30 degrees. The projection of the hot spot (SN) was marked on the patient's skin under gammacamera guidance. Using a 14-mm-wide hand-held gamma probe, the search for the SN was initiated within the marked area in the OR. Gamma probe readings ten times above the background level were considered significant. No blue dye was used for the biopsy technique. After excision, the SNs were conveniently identified and sent to the pathology laboratory where a special protocol was applied including 2 mm inclusion blocks and several sections per block, up to 30 or more slices in a standard 1 cm SN. Sections were stained with hematoxilineosin (H&E) and immunostains were also obtained using a commercially available anti-cytokeratin preparation. Axillary non-sentinel nodes were simply bisected. The primary tumour and the rest of the lymph nodes were conventionally assessed with H&E. Micrometastasis were defined as nodal groups of epithelial neoplastic cells with a diameter under 2 mm If initially detected on the immunostains, micrometastases had to be morphologically noticeable on the corresponding H&E sections, otherwise they were not considered.
Statistics and meta-analysis procedure
Our own data were analysed separately, and were later 'pooled' with the results from a comprehensive survey of the literature. For this purpose, an attempt was made to identify all the relevant studies from January 1996 to October 1999, according to the return of a MEDLINE query that used the linked terms of 'sentinel node' and 'breast cancer' as the key words. Only english-written, peer-reviewed prospective studies containing data from at least 50 patients with early breast cancer comparing SBN with ALND were considered. The constraint of 50 patients was an arbitrary threshold to avoid small series, in which the results of the SNB could be potentially affected by the corresponding learning curves. Also, in each study, the rates of true and false results had to be clearly stated or easily drawn from the reported data.
Technical success rate was defined as numbers of patients with successful SNB over the total number of patients. Taking histologic analysis of the ALND as the 'golden standard', the final result of SNB for each patient was categorised as true positive (TP), true negative (TN) or false negative (FN). The following accuracy parameters were considered: sensitivity (S = TP/TP + FN), false-negative rate (FNR = FN / FN + TP), and negative predictive value (NPV = TN / TN + FN). The 95% confidence sensitivity intervals (95% CI) were calculated according to Diamond's approximation to the exact method for proportions [9] . As SNB has no false positive results, specificity and positive predictive values were not considered.
In the meta-analysis, a model of fixed and random effects was used for pooling specificity that was weighted by the inverse of the variance [10] . A meta-analysis is done to sintetize the information available from the literature, so individual observed trends from similar studies can be combined to reach statistical significance. Two important factors must be controlled, heterogeneity among series and the relative contribution of each study. The random effect model controls heterogeneity. As for the relative strengh of each study, sample size is important and the analysed variables are usually given a 'weight' factor, in our case the inverse of the variance, which was chosen because it does not biass the calculated pooled sensitivity. However, other weight factors may be used, such as the sample size or the standard error.
The logits of the sensitivity and 1-specificity were taken and pooled, and the pooled sensitivity logit was then re-transformed. In this way we obtained global sensitivity and its corresponding 95% CI. Weighted and unweighted least squares linear regression were used to estimate parameters for the Summary Receiver Operating Characteristic (SROC) model. A two-parameter model was obtained by the linear regression of the difference of the logits D (D = logit(sensitivity) -logit( I-specificity)) on the sum of the logits S (S = logit(sensitivity) + Iogit( I-specificity)) whereby D = a + bS, in order to test whether the log odds ratio was associated with test thresholds [11] , The variance of the difference between logits was used to weight each observation. A one-parameter SROC model was also estimated by fitting only the intercept (S = 0). Because there are no false positives, a value of 0.5 was added to all the cells in order to avoid errors in the estimations of the logits. The area under the SROC curve was used to help assess the efficacy of the technique. Owing to increased patient numbers, pooled confidence intervals result in a much narrower range compared with single-study confidence intervals, thus estimates of sensitivity improve.
Results

Local SNB results
Our 132 patients had a mean age of 60.3 years (range 32-86). Tumour size ranged from 0.7-5 cm in greater dimension, with a mean value of 1.9 ± 1.0 cm (±SD). Thirty-five patients (26.5%) presented with non-palpable tumours. Breast-conserving surgery was indicated in 77 patients (58.3%). Most patients had an infiltrating ductal carcinoma (86%), while lobular carcinoma was present in 4%, DCIS in 4%, medular carcinoma in 4%, and 2% other.
The technical success rate in our series was 96% (literature range 68.7%-98.7%, mean 90.6%). The number of SNs per patient ranged from 1-6, with a mean of 2.0 ± 1.4 (± SD). In the remaining of the ALND, a mean of 12.6 ± 5.1 (±SD) nodes were recovered per patient. Seventy-three percent of SNs were found at axillary level 1, although important variations were noted, such as SNs at the internal mammary basin in 21% of cases, usually associated with simultaneous axillary SNs, intramammary SNs in 3%, complex drainage in 2%, and direct level 3 SN in 1%.
Compared with the histological analysis of complete ALND, the SNB yielded 48 true positives, 77 true negatives and 2 false-negatives. Thus, sensitivity of the technique was 96%, negative predictive value 97.3%, and false-negative rate 4%. In 48% of the true positive cases, the SN was the only involved node (by micromestastases only in 6 cases -12.5% -). Thanks to the SNB technique seven patients were upstaged from NO to Nl (stage II): six cases of SN-only micrometastases that would have not been detected on node bisection, and one patient with metastatic intramammary SN and negative ALND, undergoing lumpectomy. Also, in two patients, metastatic internal mammary SNs were found (with positive ALND).
Meta-analysis results
Eighteen studies were identified in the literature meeting our selection criteria [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , to which we added our own data. No classification of the series was done because they were very similar in design, only differing in the number of cases. The average sample size for the studies was 104, with a range from 50-443. In the regression analysis, the mean square error fit and slope values indicated that the estimated S was not significantly different from zero in the two-parameter model, thus threshold heterogenetity was not accountable. Therefore, the final analysis was based on the oneparameter model, and there were no differences between weighted and unweighted data. The log summary odds ratio was 7.36 (95% CI: 6.89-7.37) for the unweighted one-parameter model. Individual as well as pooled sensitivity and corresponding 95% CI data are shown in Table 1 . Estimated sensitivity ranged from 83%-100%. Pooled sensitivity, accounting for random and fixed effects was 91% (95% CI: 89%-93%), and the pooled area under the SROC curve was 0.9967 for the weighted method. These results mean that combined sensitivity and specificity approach unity in the 'pooled data' analysis, which is the ideal for a diagnostic test.
Discussion
An approach to the validity ofSNB
Due in part to the pressure from medical and public awareness as to the potential benefits of SNB over the more conventional ALND, there is a growing interest in embracing this new technique. Such a moment is similar to the historical transition from mastectomy to breastconserving surgery a few years ago. Some centres have already begun to offer SNB as an option for their patients to consider, specially in Tj patients. For instance, investigators from the Memorial Sloan-Kettering Cancer Center in New York [23] have recently reported a series in which SNB was compared with ALND in 104 patients. After that study, ALND is not being offered on a routine basis, but rather only if the intraoperative analysis of the SN happens to be positive. Several other US centres have also reported a similar approach [25, 27, 28] , while in Europe some pioneer dutch centres have adopted the same policy (R.Valdes-Olmos, personal communication)."
A group from Milan has recently reported very good results for SNB in a large series [24] . The authors are now proposing a randomized prospective study comparing SNB versus conventional ALND to be started early in the year 2000. Therefore, there seem to be two different approaches to the validity of SNB: the first is be to compare SNB with the reference technique (ALND) in order to calculate the standard accuracy parameters (S, FNR, NPV). Based on the present meta-analysis results, we believe that there is enough accumulated evidence in the literature to support SNB as a safe substitute for ALND. The second approach is focussed on the prognostic and therapeutic impact of SNB, considering the long-term application of the technique. As already mentioned, the group from Milan has devised a randomized study to reach definite conclusions on the impact of SNB, while in the UK, a group from Cardiff has proposed a similar study, known as the ALMANAC project [30] . Obviously, such randomized studies are best suited to address some of the present uncertainty about the prognostic and therapeutic implications of SNB in the long run. However, their main drawback is that a long follow-up period will be required to reach statistical significance, perhaps ten years or so. Given the excellent results already obtained by many groups with the SNB, it will be very difficult to wait for those results to come in. On the other hand, we should also consider that the rapidly developing field of prognostic factors in breast cancer may render the effort of such randomized studies useless. Future management of adjuvant therapy may depend on tumor-related factors rather than on nodederived information. Meanwhile, however, we should not relinquish the opportunity to assess lymph-node status using a minimally invasive technique and sparing our patients the undesired effects of ALND.
As an alternative approach, our assessment of the validity of SNB in clinical practice is based on statistical grounds, considering both local and global experience. Locally, it is important to consider the learning curve, as with other surgical techniques. It has recently been shown that ALND should be performed while learning SNB, and that only after documentation of high SNB sensitivity can ALND be omitted, otherwise a decrement in patient survival could happen because of understaging [31] . In our own comparative study, we set out to reach high sensitivity for the SNB, and also aimed for an increased value in the lower limit of the sensitivity confidence interval. Such confidence interval describes a range of sensitivity values in the patient sample within which lies the true SNB sensitivity value in our target population of early breast cancer patients. The more patients included in a particular series, the more assurance is reached in the estimated sensitivity [9] . Obviously, sensitivity and its associated 95% CI depend solely on the fraction of node-positive patients. Therefore, to reach our goals, at least 50 positive patients were required, meaning that the total number in the series had to rise considerably, up to 132.
Beyond our local experience, meta-analysis results support the view that SNB is a valuable technique, showing a high sensitivity value and a very narrow confidence interval, with a lower limit of 89% after the inclusion of more than 2500 patients from various clinical backgrounds. With such figures from local and combined experience, we feel confident dealing with a dependable and highly sensitive technique for the detection of nodal involvement.
Last, but not least, there is the problem with the 'golden standard'. The key issue in this whole process of granting validity to the SNB is the false-negative rate or the 'lack of sensitivity', which could affect patient management and even survival. In our series, FN rate was 4% (2 FN cases out of 50 node-positive patients) in the first 132 patients. Being a complex and multidisciplinary technique, there were many potential sources of error, notwithstanding the negative impact of the learning curve. In fact, both FN patients occurred within the first half of our series. However, we must also consider the possibility that ALND does not make a perfect standard for comparison, and that it may carry some risk of false-negativity for nodal disease on its own [32] [33] [34] . Considering the upstaging effect of SNB in our patients, we have calculated a false-negative rate for ALND as high as 14%: 7 upstaged patients out of 50 finally node-positive. The fact that we were not fully aware of such limitations of ALND does not lessen its importance. Could this fact explain the considerable survival failure rate in (previously considered) nodenegative patients? Perhaps SNB should be used to redefine node-negative breast cancer. SNB can identify metastases in nodes that would have been left behind, including intramammary, apical and internal mammary chain lymph nodes, as well as significant micrometastatic disease that is not addressed by the current practice of simple node bisection [34, 35] . This is a most important collateral contribution of the SNB to breast cancer staging. Stage I-II shift because of sentinel-only node positivity, even with micrometastasis, means a change in adjuvant therapy according to present standards with an expected positive impact on survival. Therefore, we believe that SNB should replace ALND not only because it is less invasive, but also because it has the potential to improve staging in a very significant way.
Conclusions
It has been shown that SNB is a practical alternative to ALND for most patients with invasive breast cancer. Before embracing the new technique and abandoning ALND, it is advisable to prove its value in the clinical setting. A high profile in the local standards ofs sensitivity, predictive value, and false-negative rate should be achieved. In that respect, we propose using the analysis of both local and global sensitivity and its associated confidence interval as an approach to validity. We believe that, although elegant, long term randomized studies may be impractical in the present scene of breast cancer management. Finally, in our view, because it has the ability to upstage considerable numbers of patients, SNB is superior to conventional ALND as the preferred method for lymph-node assessment in breast carcinoma.
